List of Excipients in Branded Drug CHILDRENS FLONASE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Haleon US Holdings LLC	CHILDRENS FLONASE	fluticasone propionate	0135-0582	BENZALKONIUM CHLORIDE
Haleon US Holdings LLC	CHILDRENS FLONASE	fluticasone propionate	0135-0582	CARBOXYMETHYLCELLULOSE SODIUM
Haleon US Holdings LLC	CHILDRENS FLONASE	fluticasone propionate	0135-0582	CELLULOSE, MICROCRYSTALLINE
Haleon US Holdings LLC	CHILDRENS FLONASE	fluticasone propionate	0135-0582	DEXTROSE

Last updated: August 9, 2026

Children's Flonase Allergy Relief is an OTC fluticasone propionate nasal spray for children aged 4 and older. Its commercial position depends more on device performance, dosing confidence, tolerability, packaging, and retailer access than on composition-of-matter exclusivity. The formulation uses a conventional aqueous suspension system with microcrystalline cellulose/carboxymethylcellulose sodium, polysorbate 80, dextrose, benzalkonium chloride, phenethyl alcohol, purified water, and pH adjustment. The strongest commercial opportunities are preservative-free delivery, improved pediatric usability, differentiated sensory performance, and private-label or retailer-exclusive products.

Children's Flonase Excipient Strategy and Commercial Opportunities

What is Children's Flonase and how is it regulated?

Children's Flonase Allergy Relief contains fluticasone propionate, a synthetic corticosteroid administered intranasally for seasonal and perennial allergic rhinitis. Each spray delivers 50 micrograms of fluticasone propionate. The US OTC product is labeled for children aged 4 years and older and adults [1].

Attribute	Children's Flonase Allergy Relief
Active ingredient	Fluticasone propionate
Strength	50 mcg per spray
Dosage form	Aqueous nasal suspension spray
US indication	Relief of allergy symptoms, including nasal congestion, sneezing, runny nose and itchy, watery eyes
Pediatric use	Children 4 years and older
US regulatory status	OTC product approved through the FDA prescription-to-OTC pathway
Commercial sponsor	Haleon, following the separation of GSK Consumer Healthcare
Primary competitors	Generic fluticasone propionate sprays, Flonase Sensimist, Nasacort Allergy 24HR, Rhinocort Allergy, and retailer brands

The original Flonase prescription product was approved under FDA NDA 020833. The OTC switch expanded access and created a mass-market allergy franchise rather than a prescription-only product [2]. Children's Flonase is sold as a pediatric-labeled OTC presentation of the same active pharmaceutical ingredient and spray technology.

What excipients are used in Children's Flonase?

The listed inactive ingredients are:

Excipient	Formulation role
Microcrystalline cellulose and carboxymethylcellulose sodium	Suspending and viscosity-control system
Polysorbate 80	Wetting and dispersion aid
Dextrose	Tonicity and formulation-balancing agent
Benzalkonium chloride	Preservative
Phenethyl alcohol	Preservative and antimicrobial-supporting excipient
Purified water	Vehicle
Hydrochloric acid, where used for adjustment	pH control

The formulation is a suspension rather than a true solution. Fluticasone propionate has very low water solubility, so the product depends on controlled particle size, wetting, suspension stability, valve reproducibility, and patient shaking before use.

Why the suspension system matters

The microcrystalline cellulose/carboxymethylcellulose combination provides a structured aqueous vehicle. It helps keep drug particles dispersed between doses while allowing the spray pump to deliver a reproducible plume. Polysorbate 80 improves wetting of hydrophobic fluticasone propionate particles.

This excipient architecture creates several development constraints:

• Drug particles must remain uniformly dispersed during storage.
• The suspension must redisperse after normal settling.
• The pump must deliver consistent dose weight and spray pattern.
• The formulation must avoid excessive viscosity that reduces atomization.
• Preservatives must remain effective without increasing nasal irritation.
• The product must remain stable across temperature and shipping conditions.

A competitor can match the qualitative ingredient list and still fail on spray geometry, particle distribution, plume force, dose uniformity, priming, or patient-perceived irritation.

What excipient strategy supports the current product?

The current strategy is conservative and established. It uses excipients with broad pharmaceutical precedent and a low-cost manufacturing profile.

Suspension stability

Microcrystalline cellulose and sodium carboxymethylcellulose are widely used in nasal suspensions because they can create a low-shear structured vehicle. During storage, the formulation may settle slowly. During shaking and actuation, it must redisperse sufficiently to deliver a uniform dose.

The commercial advantage is manufacturing familiarity. The limitation is that the product requires patient handling and may produce variable dosing if the bottle is not shaken correctly or if the suspension is near the end of its usable life.

Antimicrobial protection

Benzalkonium chloride and phenethyl alcohol provide preservation in a multidose container. Multidose nasal sprays require protection from microbial contamination introduced through repeated use.

The commercial tradeoff is tolerability. Preservatives can contribute to nasal dryness or irritation in some users. The clinical and commercial relevance is greater in chronic allergy treatment, where patients may use the product repeatedly over long periods.

Wetting and dispersion

Polysorbate 80 supports wetting of the active ingredient and helps maintain a uniform dispersion. Surfactant concentration must be controlled because excess surfactant can affect foaming, taste, nasal sensation, and spray behavior.

Tonicity and sensory profile

Dextrose contributes to the formulation's osmotic balance. Tonicity affects comfort, burning, runny nose, and post-dose drainage. For a pediatric product, small changes in sensory performance can affect willingness to continue treatment.

What formulation patents protect Children's Flonase?

The original fluticasone propionate composition-of-matter and product patents are expired or no longer central to US commercial exclusivity. The principal commercial protection for Children's Flonase is therefore not a live monopoly over the active ingredient.

Potentially relevant protection can instead arise from:

1. Specific suspension compositions.
2. Particle-size distributions.
3. Nasal spray pump and actuator systems.
4. Dose-counter mechanisms.
5. Container-closure configurations.
6. Manufacturing processes.
7. Stability improvements.
8. Preservative-free or low-preservative formulations.
9. Pediatric packaging and tamper-evident systems.
10. Trademarks and trade dress.

A composition patent covering a particular excipient ratio or particle-size range may have value only if it produces a measurable performance advantage and is difficult to design around. Broad claims directed to conventional excipients are more vulnerable to invalidity and obviousness challenges.

How strong is the patent estate?

The patent estate is weak for blocking generic entry based solely on the active ingredient. It can be stronger for differentiated delivery systems if the claims cover validated performance attributes rather than a routine ingredient substitution.

Protection category	Strategic strength
Fluticasone propionate active ingredient	Low; mature and broadly available
Basic aqueous suspension	Low to moderate
Specific excipient ratio	Moderate if linked to stability or delivery data
Pump and actuator	Moderate, depending on claim scope and ownership
Dose counter and packaging	Moderate
Pediatric labeling	Low as a patent barrier
Trademark and brand recognition	High commercial value, but not a generic-entry barrier
Manufacturing know-how	Moderate; difficult to observe but not always legally exclusive

When does Children's Flonase lose exclusivity?

Children's Flonase does not have a meaningful remaining small-molecule exclusivity period comparable to a newly approved prescription drug. The original fluticasone propionate product has been marketed for decades, and generic fluticasone propionate nasal sprays are available in the US.

The current competitive barriers are:

• FDA approval requirements for nasal suspension products.
• Device and pump equivalence.
• Product quality and dose-delivery testing.
• Retail shelf placement.
• Pediatric labeling and consumer trust.
• Brand advertising.
• Trade dress and trademark enforcement.
• Supply-chain scale.

The OTC product's commercial exclusivity is therefore brand-led rather than patent-led. Haleon's ability to defend share depends on consumer recognition, pharmacy distribution, price architecture, and perceived tolerability.

What is the Orange Book status of Children's Flonase?

The original Flonase prescription NDA is associated with the FDA's Orange Book framework. However, an OTC product's practical competitive position is not determined solely by Orange Book listings. Generic and private-label competitors can enter through abbreviated or other FDA pathways, subject to the applicable regulatory requirements for the product and device.

For a nasal spray, the critical legal and regulatory questions include:

• Whether an abbreviated application references the relevant NDA.
• Whether the competitor must address listed patents.
• Whether the product is therapeutically equivalent.
• Whether the pump and container-closure system meet FDA requirements.
• Whether the product is sold under a different OTC regulatory route.
• Whether the competitor makes a different claim set or dosage presentation.

The main commercial conclusion is that Orange Book-listed patents are unlikely to provide a durable barrier against all fluticasone propionate nasal spray competition.

Which companies are challenging Children's Flonase?

The competitive set includes manufacturers of generic fluticasone propionate nasal sprays and branded OTC allergy products. Competition comes from both pharmaceutical companies and large consumer-health retailers.

Competitor group	Examples	Primary advantage
Generic fluticasone manufacturers	Multiple FDA-approved generic suppliers	Lower price and pharmacy substitution
Branded intranasal steroids	Haleon's Flonase Sensimist, Sanofi's Nasacort, Perrigo-linked and other branded products	Formulation, sensory or brand differentiation
Retailer private labels	Store-brand fluticasone products	Price and shelf placement
Alternative allergy therapies	Oral antihistamines, antihistamine nasal sprays, saline products	Convenience or symptom-specific positioning

Flonase Sensimist is a direct portfolio comparison because it uses a different delivery and sensory proposition from the traditional Flonase suspension spray. The distinction allows Haleon to segment consumers by preference rather than rely on one formulation.

How do Children's Flonase and generic fluticasone compare?

Factor	Children's Flonase	Generic fluticasone propionate nasal spray
Active ingredient	Fluticasone propionate	Fluticasone propionate
Pediatric label	Generally positioned for children 4 and older	Depends on product labeling
Price	Usually higher	Usually lower
Consumer recognition	Strong	Limited or retailer-dependent
Formulation differentiation	Established suspension and branded device	May be similar or optimized for cost
Retail access	Strong OTC presence	Strong pharmacy and private-label presence
Patent barrier	Limited	Limited
Main purchase driver	Trust, availability, perceived performance	Price and substitution

A generic can be therapeutically equivalent while differing in inactive ingredients, pump design, packaging, plume characteristics, and sensory experience. These differences create opportunities for branded products but also provide openings for new entrants.

What excipient innovations could create commercial opportunities?

Preservative-free multidose systems

A preservative-free Children's Flonase alternative could target parents concerned about nasal irritation or repeated exposure to benzalkonium chloride. The technical challenge is microbial control in a multidose package.

Commercially viable options include:

• Unit-dose containers.
• One-way valve systems.
• Sterile multidose pumps.
• Airless or contamination-resistant packaging.
• Alternative preservative systems with acceptable nasal tolerability.

A preservative-free product would need to justify higher packaging cost through a clear consumer benefit. The strongest positioning would be comfort, chronic-use suitability, or reduced irritation rather than a generic "clean label" claim.

Improved suspension vehicles

A new vehicle could reduce the need for vigorous shaking, improve redispersion, or provide a more consistent spray late in the bottle's life. Candidate approaches include optimized cellulose derivatives, polymer combinations, or controlled rheology systems.

The patent opportunity is stronger when the formulation is linked to data showing:

• Improved dose uniformity.
• Lower settling rate.
• Faster redispersion.
• Reduced nozzle clogging.
• Improved plume consistency.
• Better stability under temperature stress.

Low-drip and low-throat-deposition systems

Children may resist nasal products because of runoff into the throat, unpleasant taste, or post-dose drainage. A formulation-device combination that narrows the spray plume or reduces excess volume could improve adherence.

The opportunity is not limited to excipients. It may require coordinated optimization of:

• Droplet-size distribution.
• Spray cone angle.
• Actuator orifice.
• Pump stroke volume.
• Formulation viscosity.
• Surface tension.
• Patient head position and instructions.

Sensory-optimized formulations

Taste and burning can influence pediatric acceptance. Excipient changes should focus on reducing bitterness, minimizing postnasal drip, and preserving a neutral nasal sensation. Strong sweeteners or flavors may create regulatory and pediatric acceptability issues, so the preferred strategy is often reducing drainage rather than masking it.

Sustainable packaging

A lower-plastic bottle, recyclable actuator, or reduced-material package could support retailer sustainability requirements. The primary technical issue is maintaining dose accuracy, moisture protection, chemical compatibility, and mechanical reliability.

Packaging improvements can support trade-secret protection and design patents even when the formulation itself is difficult to protect.

What FDA regulatory issues affect a new Children's Flonase competitor?

A new product must address both drug and device performance. Key regulatory workstreams include:

• Active-ingredient identity and assay.
• Particle-size distribution.
• Delivered-dose uniformity.
• Spray content uniformity.
• Plume geometry and droplet-size distribution.
• Microbial limits and preservative effectiveness.
• Container-closure integrity.
• Stability after opening and repeated actuation.
• Priming and repriming behavior.
• Labeling for children aged 4 years and older.
• Human-factors assessment for pediatric caregivers.
• Drug-device combination-product requirements.

A formulation that changes excipients may trigger comparability questions even when the active ingredient and nominal strength remain unchanged. For a suspension spray, in vitro equivalence is central because systemic pharmacokinetics may not fully capture local nasal performance.

What manufacturing and intellectual-property barriers exist?

The active ingredient is not the main barrier. Manufacturing barriers arise from the need to control:

• Micronized fluticasone particle characteristics.
• Homogeneous bulk suspension.
• Agitation and hold times.
• Filling accuracy.
• Pump assembly.
• Nozzle cleanliness.
• Preservative distribution.
• Dose uniformity over the labeled number of sprays.

Trade secrets can protect process parameters, mixing order, shear conditions, filling procedures, and device assembly controls. These protections are useful against direct copying but do not prevent an alternative manufacturer from developing a noninfringing process.

The most defensible patent strategy would combine:

1. Composition claims covering a demonstrated stability or delivery advantage.
2. Device claims covering dose and plume performance.
3. Manufacturing claims covering reproducible suspension processing.
4. Packaging claims covering contamination control.
5. Trademark protection for the pediatric brand.

What licensing opportunities exist around Children's Flonase?

The most realistic licensing opportunities are adjacent to the product rather than tied to fluticasone propionate itself.

Potential deal categories include:

• Preservative-free multidose nasal pumps.
• Pediatric-friendly actuators.
• Low-drip spray technologies.
• Sterile or contamination-resistant packaging.
• Suspension stabilization platforms.
• Contract manufacturing for nasal suspensions.
• Retailer-exclusive private-label formulations.
• Regional OTC commercialization rights.

A licensing deal would be more attractive if the technology improves a measurable product attribute without requiring a new clinical efficacy program. Device and packaging platforms can have broader portfolio value across corticosteroids, antihistamines, decongestants, and saline products.

What revenue exposure and commercial opportunities matter most?

Haleon does not generally report Children's Flonase revenue as a separately disclosed product line. Revenue exposure is embedded within the broader Flonase and respiratory-health portfolio.

The most important commercial opportunities are:

• Premium pediatric packaging.
• Preservative-free positioning.
• Better sensory performance.
• Retailer-exclusive SKUs.
• Multipacks and seasonal allergy promotions.
• E-commerce subscriptions.
• Pharmacy and pediatrician recommendation channels.
• International adaptations for local OTC rules.
• Device upgrades that support premium pricing.

The largest threat is price erosion from generic and store-brand fluticasone. A formulation upgrade must therefore deliver a visible consumer benefit. A marginal excipient change without improved usability, comfort, or stability is unlikely to support durable pricing power.

Key Takeaways

• Children's Flonase is an OTC fluticasone propionate nasal suspension for children aged 4 and older.
• Its excipient system uses cellulose-based suspension control, polysorbate 80, dextrose, benzalkonium chloride, phenethyl alcohol, and purified water.
• Core active-ingredient patent protection is no longer the principal commercial barrier.
• The strongest defensible opportunities are in device performance, preservative-free packaging, sensory optimization, and manufacturing know-how.
• Generic and private-label competition creates substantial price pressure.
• Pediatric adherence, low-drip delivery, and reduced irritation are the clearest formulation-led differentiation areas.
• The most valuable licensing targets are nasal delivery systems and contamination-resistant multidose packaging.
• Brand, distribution, and retailer access are more important than Orange Book exclusivity for current commercial performance.

FAQs

Can Children's Flonase be reformulated without changing its FDA pathway?

A reformulation may require a supplemental application, a new application, or another FDA pathway depending on the extent of the change, the sponsor's regulatory strategy, and the effect on product performance. Changes to excipients, preservative systems, pump components, or dosing characteristics can trigger additional comparability and stability requirements.

Is benzalkonium chloride essential in Children's Flonase?

Benzalkonium chloride is used as a preservative in the labeled formulation, but it is not inherently required for every fluticasone nasal spray. A competitor could use a different preservative strategy or a preservative-free package if it demonstrates microbiological control and meets FDA requirements.

Is a preservative-free Children's Flonase product commercially viable?

Yes, but the product would likely require a higher-cost package or a redesigned multidose system. Commercial viability would depend on a clear consumer benefit, such as improved comfort, reduced irritation, or suitability for frequent use.

Can a company patent a generic fluticasone nasal spray excipient system?

A company may obtain patent protection for a novel and nonobvious composition, device, or manufacturing process. Conventional combinations of known excipients are less likely to support broad, durable claims unless linked to unexpected stability, delivery, or tolerability results.

Does Children's Flonase face biosimilar competition?

No. Fluticasone propionate is a small-molecule drug, so competitors enter through generic-drug or OTC regulatory pathways rather than biosimilar pathways.

References

1. Haleon. (n.d.). Children's Flonase Allergy Relief nasal spray: Drug facts label. DailyMed, U.S. National Library of Medicine.

2. U.S. Food and Drug Administration. (1994). Flonase (fluticasone propionate) nasal spray, NDA 020833. Drugs@FDA.

3. U.S. Food and Drug Administration. (2015). FDA approves Flonase Allergy Relief for over-the-counter use. FDA.

4. U.S. Food and Drug Administration. (2024). Orange Book: Approved drug products with therapeutic equivalence evaluations. FDA.